CA2995161A1 - 2,3,4,5-tetrahydropyridin-6-amine derivatives - Google Patents
2,3,4,5-tetrahydropyridin-6-amine derivatives Download PDFInfo
- Publication number
- CA2995161A1 CA2995161A1 CA2995161A CA2995161A CA2995161A1 CA 2995161 A1 CA2995161 A1 CA 2995161A1 CA 2995161 A CA2995161 A CA 2995161A CA 2995161 A CA2995161 A CA 2995161A CA 2995161 A1 CA2995161 A1 CA 2995161A1
- Authority
- CA
- Canada
- Prior art keywords
- 3alkyloxy
- 3alkyl
- mmol
- polyhalo
- monohalo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15186394 | 2015-09-23 | ||
| EP15186394.1 | 2015-09-23 | ||
| EP16172005 | 2016-05-30 | ||
| EP16172005.7 | 2016-05-30 | ||
| PCT/EP2016/072710 WO2017050978A1 (en) | 2015-09-23 | 2016-09-23 | 2,3,4,5-tetrahydropyridin-6-amine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2995161A1 true CA2995161A1 (en) | 2017-03-30 |
Family
ID=56985626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995161A Abandoned CA2995161A1 (en) | 2015-09-23 | 2016-09-23 | 2,3,4,5-tetrahydropyridin-6-amine derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180334447A1 (https=) |
| EP (1) | EP3353163B1 (https=) |
| JP (1) | JP2018527387A (https=) |
| KR (1) | KR20180053357A (https=) |
| CN (1) | CN108026069A (https=) |
| AU (1) | AU2016328589A1 (https=) |
| BR (1) | BR112018005591A2 (https=) |
| CA (1) | CA2995161A1 (https=) |
| EA (1) | EA035026B1 (https=) |
| HK (1) | HK1254800A1 (https=) |
| IL (1) | IL258217A (https=) |
| MX (1) | MX2018003565A (https=) |
| TW (1) | TW201726651A (https=) |
| WO (1) | WO2017050978A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019208509A1 (en) * | 2018-04-23 | 2019-10-31 | Shionogi & Co., Ltd. | Bicyclic heterocycle derivatives having selective bace1 inhibitory activity |
| TW202014191A (zh) | 2018-04-27 | 2020-04-16 | 日商鹽野義製藥股份有限公司 | 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物 |
| CN114380736B (zh) * | 2020-10-21 | 2023-10-03 | 复旦大学 | 一种2,3,4,5-四氢吡啶类化合物的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US20120258961A1 (en) * | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
| US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| KR101730937B1 (ko) * | 2010-06-09 | 2017-04-27 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CN106029639B (zh) * | 2014-02-19 | 2019-01-08 | H.隆德贝克有限公司 | 治疗阿尔茨海默病的bace1抑制剂的2-氨基-3，5，5-三氟-3，4，5，6-四氢吡啶 |
-
2016
- 2016-09-21 TW TW105130403A patent/TW201726651A/zh unknown
- 2016-09-23 KR KR1020187010344A patent/KR20180053357A/ko not_active Withdrawn
- 2016-09-23 CN CN201680055231.XA patent/CN108026069A/zh active Pending
- 2016-09-23 AU AU2016328589A patent/AU2016328589A1/en not_active Abandoned
- 2016-09-23 WO PCT/EP2016/072710 patent/WO2017050978A1/en not_active Ceased
- 2016-09-23 HK HK18113885.1A patent/HK1254800A1/zh unknown
- 2016-09-23 JP JP2018514794A patent/JP2018527387A/ja active Pending
- 2016-09-23 BR BR112018005591A patent/BR112018005591A2/pt not_active Application Discontinuation
- 2016-09-23 EP EP16770283.6A patent/EP3353163B1/en active Active
- 2016-09-23 EA EA201890769A patent/EA035026B1/ru not_active IP Right Cessation
- 2016-09-23 MX MX2018003565A patent/MX2018003565A/es unknown
- 2016-09-23 US US15/761,304 patent/US20180334447A1/en not_active Abandoned
- 2016-09-23 CA CA2995161A patent/CA2995161A1/en not_active Abandoned
-
2018
- 2018-03-19 IL IL258217A patent/IL258217A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3353163A1 (en) | 2018-08-01 |
| TW201726651A (zh) | 2017-08-01 |
| WO2017050978A1 (en) | 2017-03-30 |
| EP3353163B1 (en) | 2020-02-05 |
| BR112018005591A2 (pt) | 2018-10-09 |
| HK1254800A1 (zh) | 2019-07-26 |
| AU2016328589A1 (en) | 2018-03-01 |
| US20180334447A1 (en) | 2018-11-22 |
| JP2018527387A (ja) | 2018-09-20 |
| EA035026B1 (ru) | 2020-04-20 |
| EA201890769A1 (ru) | 2018-09-28 |
| MX2018003565A (es) | 2018-06-18 |
| CN108026069A (zh) | 2018-05-11 |
| IL258217A (en) | 2018-05-31 |
| KR20180053357A (ko) | 2018-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2852355C (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| CA2853891C (en) | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| EP2064192A2 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| KR20130090793A (ko) | 베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5-아미노-3,6-디하이드로-1ｈ-피라진-2-온 유도체 | |
| AU2004255191A1 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| CA3131385A1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| EP3898614A1 (en) | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer | |
| EA031041B1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| TW202227399A (zh) | 化合物及使用方法 | |
| KR20230031321A (ko) | 치환된 페닐 또는 피리디닐 모이어티를 갖는 serd 트리시클릭 화합물의 제조 방법 | |
| JP2024178221A (ja) | Ｐｄ－ｌ１拮抗薬化合物 | |
| EP3353163B1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| JP2024510778A (ja) | １，３－置換シクロブチル誘導体及びその使用 | |
| AU2020394597A1 (en) | 1,2,4-oxadiazole derivatives as liver X receptor agonists | |
| NL1029139C2 (nl) | Nieuwe aminopyridinederivaten en hun gebruik als farmaceutica. | |
| WO2012073146A1 (en) | Kat ii inhibitors | |
| WO2020205835A1 (en) | Fused polycyclic pyridone compounds as influenza virus replication inhibitors | |
| RU2823231C1 (ru) | Соединение-антагонист PD-L1 | |
| TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
| CA3039586A1 (en) | 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220323 |